Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Signifor Approval Highlights Success Of Novartis’ Parallel Development Strategy

Executive Summary

Following its approval in Europe earlier in 2012, the FDA approval of Signifor for Cushing’s disease is just the latest piece of a strategy to bring the injectable to market in multiple indications, including acromegaly.

You may also be interested in...



Camurus’ R&D Receives Boost As Novartis Exercises Octreotide Option

The race to develop an easier-to-administer and less painful injection of octreotide for acromegaly is getting hotter, as Novartis takes over development of the Swedish company’s novel subcutaneous long-acting octreotide formulation.

IQWiG Backs Novartis’ Jetrea, Drops Almirall’s Constella On Same Day

Germany’s IQWiG has backed Novartis’ Jetrea for VMT, albeit with restricted indication, but knocked back Almirall’s Constella, citing study irrelevance.

EU Court Ruling Makes Orphan Drug Application Route More Attractive

A ruling by the EU’s Court of Justice overturning a previous decision by the European Commission on Laboratoire CTRS’s liver drug should make orphan drug applications more attractive in the region.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

PS054992

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel